In:
Frontiers in Bioengineering and Biotechnology, Frontiers Media SA, Vol. 11 ( 2023-2-10)
Abstract:
Exogenous insulin therapy is the mainstay treatment for Type-1 diabetes (T1D) caused by insulin deficiency. A fine-tuned insulin supply system is important to maintain the glucose homeostasis. In this study, we present a designed cell system that produces insulin under an AND gate control, which is triggered only in the presence of both high glucose and blue light illumination. The glucose-sensitive GIP promoter induces the expression of GI-Gal4 protein, which forms a complex with LOV-VP16 in the presence of blue light. The GI-Gal4:LOV-VP16 complex then promotes the expression of UAS-promoter-driven insulin. We transfected these components into HEK293T cells, and demonstrated the insulin was secreted under the AND gate control. Furthermore, we showed the capacity of the engineered cells to improve the blood glucose homeostasis through implantation subcutaneously into Type-1 diabetes mice.
Type of Medium:
Online Resource
ISSN:
2296-4185
DOI:
10.3389/fbioe.2023.1052607
DOI:
10.3389/fbioe.2023.1052607.s001
DOI:
10.3389/fbioe.2023.1052607.s002
DOI:
10.3389/fbioe.2023.1052607.s003
DOI:
10.3389/fbioe.2023.1052607.s004
DOI:
10.3389/fbioe.2023.1052607.s005
DOI:
10.3389/fbioe.2023.1052607.s006
DOI:
10.3389/fbioe.2023.1052607.s007
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2023
detail.hit.zdb_id:
2719493-0